Aardvark Therapeutics, Inc. (AARD)
NASDAQ: AARD · Real-Time Price · USD
7.22
+0.03 (0.42%)
Aug 12, 2026, 9:56 AM EDT - Market open

Aardvark Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22
Operating Income
-73.96-62.73-22.79-7.42-11.36
Net Income
-33.91-57.59-20.59-7.21-13.56
Earnings Per Share
-3.21-2.93-5.15-1.82-3.49
EPS Growth
-----

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22
Cash & Investments
73.87110.0373.669.9916.11
Total Debt
0.680.440.780.160.26
Net Cash (Debt)
73.19109.5972.889.8315.84
Net Cash Growth
-48.15%50.36%641.67%-37.97%-
Net Cash Per Share
3.365.5818.242.484.07

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22
Operating Cash Flow
-69.41-54.17-18.09-5.82-5.82
Capital Expenditures
-0-0.1-0.11--
Free Cash Flow
-69.41-54.27-18.2-5.82-5.82
Free Cash Flow Growth
-----

Valuation

Selected indicators aren't available for this stock.